SuperworthGyre Therapeutics shares outstanding GYRE
Diluted shares outstanding, averaged over each quarter, from 2010.
- Latest quarter, to Jun 30, 2026
- 100.6M
- On a year earlier
- +12.8%
- more shares
Gyre Therapeutics had 100.6M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 12.8% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 91.2M | +6% |
| FY2024 | 86M | +19% |
| FY2023 | 72.5M | +3323% |
| FY2022 | 2.1M | +1% |
| FY2021 | 2.1M | +42% |
| FY2020 | 1.5M | +84% |
| FY2019 | 802.7K | +1% |
| FY2018 | 796.3K | +162% |
| FY2017 | 303.4K | +468% |
| FY2016 | 53.4K | +149% |
| FY2014 | 21.5K | +0% |
| FY2013 | 21.4K | +0% |
| FY2012 | 21.3K | +1% |
| FY2011 | 21.2K | +16% |
| FY2010 | 18.2K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 100.6M | +13% | |
| Q1 FY26 | 91.3M | −10% | |
| Q4 FY25 | 91.2M | +6% | |
| Q3 FY25 | 104M | +1% | |
| Q2 FY25 | 89.2M | −13% | |
| Q1 FY25 | 102M | −1% | |
| Q4 FY24 | 86M | +19% | |
| Q3 FY24 | 102.6M | +30% | |
| Q2 FY24 | 102.2M | +30% | |
| Q1 FY24 | 102.6M | +30% | |
| Q4 FY23 | 72.5M | +3323% | |
| Q3 FY23 | 78.9M | +3659% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Gyre Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.